Moody Aldrich Partners LLC Sells 47,301 Shares of Verona Pharma PLC American Depositary Share $VRNA

Moody Aldrich Partners LLC lowered its holdings in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) by 49.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 49,302 shares of the company’s stock after selling 47,301 shares during the period. Moody Aldrich Partners LLC’s holdings in Verona Pharma PLC American Depositary Share were worth $4,663,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its stake in shares of Verona Pharma PLC American Depositary Share by 14.0% during the 1st quarter. GAMMA Investing LLC now owns 1,837 shares of the company’s stock worth $117,000 after buying an additional 225 shares during the last quarter. Cambridge Investment Research Advisors Inc. boosted its position in Verona Pharma PLC American Depositary Share by 31.3% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 6,168 shares of the company’s stock valued at $392,000 after purchasing an additional 1,469 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in Verona Pharma PLC American Depositary Share by 366.0% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,486 shares of the company’s stock valued at $720,000 after purchasing an additional 9,021 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. bought a new position in Verona Pharma PLC American Depositary Share in the first quarter valued at approximately $284,000. Finally, GF Fund Management CO. LTD. increased its position in shares of Verona Pharma PLC American Depositary Share by 528.7% during the 1st quarter. GF Fund Management CO. LTD. now owns 9,764 shares of the company’s stock worth $620,000 after purchasing an additional 8,211 shares during the last quarter. 85.88% of the stock is currently owned by institutional investors and hedge funds.

Verona Pharma PLC American Depositary Share Price Performance

Shares of VRNA opened at $106.91 on Friday. The company’s 50-day moving average is $106.51 and its 200-day moving average is $94.01. The company has a debt-to-equity ratio of 0.87, a current ratio of 10.71 and a quick ratio of 10.54. The firm has a market capitalization of $9.21 billion, a PE ratio of -107.99 and a beta of 0.05. Verona Pharma PLC American Depositary Share has a fifty-two week low of $31.09 and a fifty-two week high of $106.93.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) last announced its earnings results on Wednesday, August 6th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of ($0.01) by $0.14. The business had revenue of $103.14 million during the quarter, compared to the consensus estimate of $90.41 million. Verona Pharma PLC American Depositary Share had a negative net margin of 36.62% and a negative return on equity of 21.12%. Equities analysts forecast that Verona Pharma PLC American Depositary Share will post -1.95 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on VRNA. Cantor Fitzgerald reissued an “overweight” rating and issued a $100.00 target price on shares of Verona Pharma PLC American Depositary Share in a research note on Wednesday, October 8th. Wells Fargo & Company downgraded shares of Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating and decreased their price objective for the company from $138.00 to $107.00 in a research report on Thursday, July 10th. BTIG Research cut shares of Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 10th. Canaccord Genuity Group downgraded shares of Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating and set a $107.00 target price for the company. in a research note on Wednesday, July 9th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Verona Pharma PLC American Depositary Share in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $109.00.

Verona Pharma PLC American Depositary Share Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.